President Trump directed his administration to help states import drugs from Canada. But a proposal to alter a Medicare ...

The president said he would build on the Medicare drug-price negotiation program begun under Joe Biden, but supports a change ...

President Donald Trump signed an executive order on Tuesday that lowers drug prices through the Medicare drug price ...

President Donald Trump’s promise to impose tariffs on pharmaceutical imports is raising red flags among generic drugmakers and industry experts, who warn that such a move could lead to increased drug ...

Many of the directions included in the order will be familiar to those who watched drug pricing policy closely during the ...

JC Scott, CEO and president of The Pharmaceutical Care Management Association, discusses current efforts in increasing biosimilar adoption and pharmacy benefit manager (PBM) reform.

Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday it has obtained an interchangeability approval for ...

The development marks a key regulatory milestone for the company and reinforces investor confidence in Biocon’s growing biosimilar portfolio. The newly approved drug, JOBEVNE (bevacizumab-nwgd ...

Expiring patents can be a catalyst for M&A in the life sciences industry as pharmaceutical and biotechnology companies seek ...

The action is intended to build upon the existing program for Medicare drug price negotiations, which was created by the ...

Biocon Biologics' Jobevne, a biosimilar of Avastin, approved by the FDA, expanding oncology portfolio and access to ...

The U.S. Food and Drug Administration has designated Celltrion Inc.’s YUFLYMA (adalimumab-aaty), as an interchangeable biosimilar to Humira.